Results 201 to 210 of about 111,826 (307)

Pregnancy as a risk factor for central serous chorioretinopathy: A systematic review and meta‐analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose Pregnancy induces significant changes in the body, including increased peripheral and choroidal blood perfusion and an increased systemic corticosteroid level. Here, we systematically reviewed the evidence on pregnancy as a risk factor for developing central serous chorioretinopathy (CSC) and conducted a meta‐analysis to obtain a ...
Nathalie Skovgaard Eriksen, Zainab Fakhril‐din, Riccardo Fasana, Rodrigo Anguita, Elon H. C. van Dijk, Lorenzo Ferro Desideri, Jakob Grauslund, Michael Stormly Hansen, Oliver Niels Klefter, Armin Motaabbed, Line Petersen, Prithvi Ramtohul, Mehmet Cem Sabaner, Osman Savran, Miklos Schneider, Yousif Subhi   +15 more
wiley   +1 more source

Evaluation of the Effect of IL-1 Antagonists on Pituitary Function. [PDF]

Int J Endocrinol
Aktas Koc F, Sariakcali B, Sahin A.
europepmc   +1 more source

Seasonal variation in the incidence of central serous chorioretinopathy: A systematic review and meta‐analysis

Acta Ophthalmologica, EarlyView.
Abstract Central serous chorioretinopathy (CSC) is a chorioretinal disease characterised by serous subretinal fluid (SRF) in the macula, resulting in sudden central vision loss. It predominantly affects working‐age adults, particularly men aged 30 to 60 years.
I. Made Ferdiko Hutamadella, Emil Ørnberg, Mark P. Breazzano, Lasse Jørgensen Cehofski, Chui Ming Gemmy Cheung, Kristina Pfau, M. Cem Sabaner, Lorenzo Ferro Desideri, Camiel J. F. Boon, Yousif Subhi, Elon H. C. van Dijk   +10 more
wiley   +1 more source

Age‐ and Sex‐Adjusted Body Mass Index Increases in Childhood Acute Lymphoblastic Leukaemia Patients From Diagnosis to Five‐Year Follow‐Up

Acta Paediatrica, EarlyView.
ABSTRACT Aim Children with acute lymphoblastic leukaemia (ALL) are at risk of metabolic and cardiovascular complications. We evaluated the development of overweight and obesity for 5 years after diagnosis in children and adolescents treated for ALL. Methods The medical records of children diagnosed with ALL at one centre during 2000–2018 were assessed.
Aino Kytömäki, Anu Huurre, Päivi M. Lähteenmäki, Tero Vahlberg, Liisa S. Järvelä   +4 more
wiley   +1 more source

Human Corticotropin-Releasing Hormone Test in Patients with Hypothalamo-Pituitary-Adrenocorticai Disorders.

, 1993
Junichi Fukata, N Shimizu, Hiroo Imura, Itsuro Hibi, KOSHI TANAKA, Toshiaki Tanaka, Shoichi Nakagawa, Kazuo Takebe, Kenichi Kimura, KAORU YOSHINAGA, Kintomo Takakura, Hiroshi Demura, Minoru Irie, Yukitaka Miyachi, Noboru Yanaihara, Teruya Yoshimi, Kiyoshi Miura, Akio Kuwayama, Zensuke Ota, Yuzuru Kato, Shiro Saito, Jiro Takahara, Kozo Hashimoto, Hajime Nawata, Shigeru Matsukura   +24 more
openalex   +2 more sources

Medical Gases as Emerging Regulators of Paediatric Endocrine and Neurodevelopmental Pathways: A Mini‐Review

Acta Paediatrica, EarlyView.
ABSTRACT Aim Medical gases, including nitric oxide, carbon monoxide, hydrogen sulphide and molecular hydrogen, have emerged as key regulators of redox balance and cellular signalling. This mini‐review examines their relevance to paediatric endocrine and neurodevelopmental pathways, domains particularly sensitive to oxidative and inflammatory ...
Roberto Paparella, Fabiola Panvino, Ida Pucarelli, Luigi Tarani   +3 more
wiley   +1 more source

Comparison of oral versus intravenous glucose exposure on plasma growth hormone levels: a crossover study in healthy volunteers. [PDF]

Pituitary
Vinten AK, Jørgensen NT, Budtz-Jørgensen E, Klose M, Andreassen M.   +4 more
europepmc   +1 more source

THE EFFECT OF PICRIC AND FLAVIANIC ACIDS ON THE POTENCY OF THE FOLLICLE-STIMULATING ANTERIOR PITUITARY HORMONE

, 1940
H. Jensen, Sibylle Tolksdorf
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone. [PDF]

Int J Mol Sci
Otsuka Y, Soejima Y, Nakano Y, Suyama A, Takase R, Oguni K, Masuda Y, Omura D, Sakurada Y, Matsuda Y, Hasegawa T, Honda H, Tokumasu K, Ueda K, Otsuka F.   +14 more
europepmc   +1 more source